A double blind, double dummy, randomised, multicentre, four arm parallel group study to assess the efficacy and safety of FlutiForm™ pMDI 250/10 µg (2 puffs bid) vs Fluticasone pMDI 250 µg (2 puffs bid) plus Formoterol pMDI 12 µg (2 puffs bid) administered concurrently in adult subjects with severe persistent, reversible asthma.

Mundipharma Research Ltd0 个研究点目标入组 1,120 人开始时间: 2008年5月22日最近更新: 2012年3月19日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Mundipharma Research Ltd
入组人数: 1,120

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male or female subjects at least 18 years old.
•2. Females less than one year post-menopausal must have a negative urine pregnancy test recorded at the screening visit prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner.
•3. Known history of severe persistent, reversible asthma for = 6 months prior to the Screening Visit characterised by treatment with ICS at a dose of = 500µg fluticasone or equivalent.
•4. Demonstrated a FEV1 of = 40% to = 80% for predicted normal values (Quanjer et al., 1993) during the Screening Visit (Visit 1) and Randomisation Visit (Visit 3) following appropriate withholding of asthma medications (if applicable).
•- No ß2-agonist use on day of screening.
•- No use of inhaled combination asthma therapy on day of screening.
•- Inhaled corticosteroids are allowed on day of screening.
•5. Documented reversibility of = 15% in FEV1 in the screening phase.
•6. Demonstrated satisfactory technique in the use of the study medication.
•7. Willing and able to enter information in the electronic diary and attend all study visits.
•8. Willing and able to substitute study medication for their pre study prescribed asthma medication for the duration of the study.
•9. Written informed consent obtained.
•Inclusion criteria required following run-in:
•10. Subject has used rescue medication for at least 3 days and also had either at least one night with sleep disturbance (i.e., sleep disturbance score of = 1) or at least 3 days with asthma symptoms (i.e., a symptom score of = 1) during the last 7 days of the run-in period.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Near fatal or life-threatening (including intubation) asthma within the past year.
•2. Hospitalisation or an emergency visit for asthma within the 4 weeks before the Screening Visit.
•3. Known history of systemic (injectable or oral) corticosteroid medication within 1 month of the Screening Visit.
•4. Known history of omalizumab use within the past 6 months.
•5. Current evidence or known history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia. ‘Clinically significant’ is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study.
•6. In the investigator’s opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the Screening Visit.
•7. Significant, non-reversible, active pulmonary disease (e.g., chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).
•8. Known Human Immunodeficiency Virus (HIV)-positive status.
•9. Subject has a smoking history equivalent to 10 pack years” (i.e., at least 1 pack of 20 cigarettes /day for 10 years or 10 packs/day for 1 year, etc.).
•10. Current smoking history within 12 months prior to the Screening Visit.
•11. Current evidence or known history of alcohol and/or substance abuse within 12 months prior to the Screening Visit.
•12. Subject has taken ß-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within the past week.
•13. Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function.
•14. Current evidence or known history of hypersensitivity or idiosyncratic reaction to test medications or components.
•15. Subject has received an investigational drug within 30 days of the Screening Visit (12 weeks if an oral or injectable steroid).
•16. Subject is currently participating in a clinical study or has already received FLT3503 double-blind medication.

研究者

发起方

Mundipharma Research Ltd

相似试验

进行中（未招募）

不适用

A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FlutiForm® pMDI 125/5 µg (2 puffs bid) vs Symbicort® Turbohaler® 200/6 µg (2 puffs bid) in adolescent and adult subjects with moderate to severe persistent, reversible asthma.

EUCTR2009-017223-25-BGMundipharma Research Ltd260

进行中（未招募）

不适用

A double blind, double dummy, randomised, multicentre, four arm parallel group study to assess the efficacy and safety of FlutiForm™ pMDI 250/10 µg (2 puffs bid) vs Fluticasone pMDI 250 µg (2 puffs bid) plus Formoterol pMDI 12 µg (2 puffs bid) administered concurrently in adult subjects with severe persistent, reversible asthma.

EUCTR2007-001633-34-BGMundipharma Research Ltd508

进行中（未招募）

不适用

EUCTR2009-017223-25-PLMundipharma Research Ltd260

进行中（未招募）

不适用

EUCTR2009-017223-25-HUMundipharma Research Ltd260

进行中（未招募）

不适用

EUCTR2007-001633-34-LVMundipharma Research Ltd508